GENVOYA Drug Patent Profile

Which patents cover Genvoya, and when can generic versions of Genvoya launch?

Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and sixty-three patent family members in fifty-three countries.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Genvoya

Genvoya was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 26, 2027. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GENVOYA

International Patents:	463
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	19
Drug Prices:	Drug price information for GENVOYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GENVOYA
What excipients (inactive ingredients) are in GENVOYA?	GENVOYA excipients list
DailyMed Link:	GENVOYA at DailyMed

See drug prices for GENVOYA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GENVOYA

Constraining patent/regulatory exclusivity:

8,981,103*PED

NDA:

207561

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GENVOYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CIHR Canadian HIV Trials Network	Phase 2
Unity Health Toronto	Phase 2
Canadian Institutes of Health Research (CIHR)	Phase 2

See all GENVOYA clinical trials

Pharmacology for GENVOYA

Drug Class	Cytochrome P450 3A Inhibitor Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors HIV Integrase Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for GENVOYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GENVOYA	Tablets	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	150 mg/150 mg/ 200 mg/10 mg	207561	1	2023-04-12

US Patents and Regulatory Information for GENVOYA

GENVOYA is protected by nine US patents.

This potential generic entry date is based on patent 8,981,103.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,754,065*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,148,374*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	9,891,239*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,633,219*PED				Y

Expired US Patents for GENVOYA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	7,800,788
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	7,803,788

International Patents for GENVOYA

See the table below for patents covering GENVOYA around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	579802	Compounds for improving the efficacy of other drugs
South Africa	201400582	TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Canada	2104399	ACTIVITE ET RESOLUTION ANTIVIRALE DU 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSINE-1-YL)-1,3-OXATHIOLANE (ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE)
Taiwan	I411613

Supplementary Protection Certificates for GENVOYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2487162	122016000103	Germany		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/967 20141119
2487162	201640054	Slovenia		PRODUCT NAME: COBICISTAT OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVAT THEREOF AND DARUNAVIR OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVAT THEREOF, ESPECIALLY DARUNAVIR ETHANOLATE; NATIONAL AUTHORISATION NUMBER: EU/1/14/967/001; DATE OF NATIONAL AUTHORISATION: 20141119; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0513200	C00513200/01	Switzerland		PRODUCT NAME: EMTRICITABINE; REGISTRATION NUMBER/DATE: SWISSMEDIC 56880 25.10.2004
1564210	C 2013 033	Romania		PRODUCT NAME: ELVITEGRAVIR OPTIONAL SUB FORMA DE SARE, SOLVAT SAU HIDRATACCEPTABILFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/13/830/001, EU/1/13/830/002; DATE OF NATIONAL AUTHORISATION: 20130524; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/830/001, EU/1/13/830/002; DATE OF FIRST AUTHORISATION IN EEA: 20130524

GENVOYA market dynamics and financial trajectory (Gilead Sciences, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) — exclusivity, pricing forces, and competitor substitution

Last updated: May 29, 2026

GENVOYA (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide, “EVG/c/FTC/TAF”) has shifted from rapid uptake toward maturity as HIV treatment guidelines moved toward higher-resistance-barrier regimens and single-tablet “INSTI backbones” with improved dosing convenience. The commercial trajectory has been shaped by (1) penetration losses to newer INSTI-based single-tablets and long-acting strategies, (2) payer and contract-driven pricing pressure, and (3) patent and regulatory cliffs around TAF-based combinations and fixed-dose INSTI regimens.

---

What drives GENVOYA market dynamics in US HIV treatment?

Short answer: Formulary placement, rebate intensity, and switching away from legacy EVG/c regimens toward guideline-preferred INSTI single-tablets and, in some segments, toward two-drug and long-acting options.

Key market forces

1) Guideline-directed switching to preferred INSTIs

• GENVOYA’s clinical positioning competes with INSTI single-tablets such as Biktarvy (bictegravir/FTC/TAF) and Symtuza (darunavir/c/FTC/TAF) in relevant lines of therapy.
• Market behavior in HIV is heavily guideline and formulary mediated. When a competitor gets preferred formulary status at the class level, switching often follows.

2) Payer economics and contract structure

• Fixed-dose combinations face durable rebate and contract scrutiny. Even where GENVOYA remains clinically appropriate, payer contracting and net price determine persistence.
• Bids and formulary tiers for HIV drugs tend to reflect net price after rebates rather than list price. This amplifies uptake of lower-net-price alternatives.

3) Resistance and regimen durability

• For treatment-experienced patients, regimen durability and resistance profile matter. However, market share for fixed-dose legacy combinations often erodes when newer INSTI regimens deliver equal or better resistance barrier, tolerability, and simplifying benefits.

4) Patient adherence and switching

• HIV care pathways include periodic regimen review, especially when competitors offer better side-effect profiles, fewer drug-drug interactions, or easier transitions from older INSTI regimens.

Competitive substitution map (practical)

• Most direct US class substitution: Biktarvy (bictegravir-based INSTI single tablet) and Symtuza (PI-based boosted regimen).
• Less direct, but commercially relevant in segments: Triumeq (dolutegravir/abacavir/lamivudine) where HLA-B*5701 status and renal/hepatic criteria allow.
• Longer-horizon pressure: long-acting injectables (where eligible) and TLD-based simplification pathways can divert new starts, even if they do not fully substitute for fixed-dose oral regimens in all subgroups.

---

How has GENVOYA financial performance evolved from launch to maturity?

Short answer: Growth phase gave way to mature-share dynamics as the HIV market matured, with incremental volumes increasingly determined by formulary access and competitive switching rather than net new patient growth.

Commercial trajectory pattern for INSTI single-tablets

While the HIV market expands with new diagnoses and improved longevity, the fixed-dose combination category behaves like a mature portfolio:

• Early uptake is driven by perceived efficacy and guideline alignment.
• Midlife is dominated by payer preference and competitive positioning within INSTI class.
• Late phase is dominated by contract renewals, pharmacy benefit design, and patient switching driven by net price, prior authorization ease, and physician preference.

Revenue drivers specific to GENVOYA

• Share persistence among patients already controlled on EVG/c/FTC/TAF.
• Ability to retain access depends on rebate strength versus Biktarvy-like comparators.
• Segment mix matters: treatment-naïve vs treatment-experienced, renal impairment populations, and those seeking fixed-dose convenience.

What matters for “financial trajectory” in practice

• Net sales versus gross-to-net pressure: HIV drugs typically show meaningful rebate variability.
• Persistence/continuation: oral fixed-dose regimens often show strong continuation among stable patients; declines come from switching and lost new starts.
• Contract cycles: US covered lives and PBM contracting cause step-changes in performance when access shifts.

---

Which competitors most affect GENVOYA sales, and how do market dynamics compare?

Short answer: Biktarvy and Symtuza are the main US substitution pressures, with Triumeq and other options influencing narrower subgroups.

Side-by-side competitive pressure (high level)

Competitor	Backbone	Typical competitive angle vs GENVOYA	Market impact pathway
Biktarvy	Bictegravir/FTC/TAF	INSTI single-tablet positioning; payer preference in many formularies	New starts and switching from older INSTI regimens
Symtuza	Darunavir/c/FTC/TAF	Alternative fixed-dose option, especially for certain resistance/PI-based pathways	Switching in treatment-experienced subgroups
Triumeq	Dolutegravir/abacavir/lamivudine	Convenience and clinician familiarity; subset-appropriate	Gains/retention where abacavir use is acceptable
Other EVG/c alternatives	INSTI combinations	Incremental head-to-head	Usually incremental vs Biktarvy unless covered by PBM preferences

Implication for GENVOYA: Even if clinical differentiation remains, formularies determine volume. Over time, competitors with stronger preferred status tend to capture incremental starts and a growing share of switch demand.

---

What is the Orange Book status for GENVOYA and what does it imply for generics?

Short answer: As an FDA-approved fixed-dose combination product for HIV, GENVOYA has relied on patent and exclusivity protections that delay AB-rated generic entry of equivalent combinations; the key commercial issue is how long exclusivity and key patents last for the exact combination and key formulation or method-of-use claims.

Orange Book and exclusivity framing for fixed-dose HIV combinations

• GENVOYA is listed in FDA’s Orange Book only to the extent it has innovator drug and patent listings applicable to generic substitution. Generic entry typically requires:
  1. crossing patent barriers for the exact active-ingredient fixed-dose combination and/or
  2. receiving approval for a proposed generic with relevant certifications (Paragraph IV) or expiration-based carve-outs.
• For combination products, patent estates are usually layered:
  • composition-of-matter type claims for active pharmaceutical ingredients or protected salts/polymorphs
  • formulation claims for fixed-dose combinations
  • dosing regimen and method-of-use claims
  • sometimes manufacturing/process-related claims

Why this matters for financial trajectory

• A delayed generic entry typically stabilizes net sales by preserving covered pharmacy access and payer comfort.
• A generic entry event shifts bargaining power to payers and accelerates switching, often rapidly.

---

When do GENVOYA patents and exclusivity expire, and what launch scenarios apply?

Short answer: The critical question for GENVOYA is not only overall product exclusivity, but whether key patents covering the fixed-dose combination or protected formulation/method-of-use claims remain in force at the time of potential FDA approval for generics.

Patent estate structure that typically governs launch timing

For fixed-dose INSTI combinations, launch scenarios are usually determined by:

1. “core” combination patent expiration (composition and/or combination claims)
2. formulation or process patent lifetimes that block equivalent product approval
3. method-of-use claims that can delay certain labels or substitution decisions
4. settlement agreements that can delay an “at-risk” launch even after technical approval

Typical generic entry pathways

• Paragraph IV challenge: generic files with an ANDA claiming patents are invalid or not infringed; the first filer may seek “48-month stay” depending on litigation outcomes.
• Expiration-only entry: delayed until all listed patents expire or are no longer enforceable.

Practical financial read-through: Even when the calendar implies some near-term expiration, the controlling factor is whether the final set of listed patents for the combination and key protected aspects remain enforceable.

---

What patent litigation and Paragraph IV challenges affect GENVOYA risk?

Short answer: For GENVOYA, financial downside would come from Paragraph IV-driven generic entry timing and any settlements that change launch dates. In mature HIV combination markets, litigation outcomes tend to create discrete “cliff” effects in net sales forecasts.

How to interpret litigation for GENVOYA commercial exposure

• Determine whether challenges target patents that:
  • cover the exact fixed-dose combination
  • cover formulation/physical form or stability
  • cover method-of-use language that supports the marketed indication and label
• Monitor whether:
  • a first-filer settles (common in brand risk management for mature combinations)
  • a settlement includes a delayed entry date and a non-expiration covenant
  • court decisions invalidate or narrow key claims

Impact on revenue: Litigation does not affect revenue continuously; it affects it at filing, stay, decision, and settlement milestones that change the effective launch calendar.

---

How strong is the patent estate for GENVOYA versus generic entry threats?

Short answer: For high-selling fixed-dose HIV combinations, the patent estate typically has layered protection. The “strength” question translates into whether competitors can design around protected claims and whether the market expects settlement or final judgment before launch.

Patent estate “strength” indicators used in deal and litigation

• Number of active Orange Book patents listed for:
  • combination claims (core protection)
  • formulation and manufacturing claims (secondary blockers)
  • method-of-use claims (label-based blockers)
• History of resolved challenges:
  • repeated denials or sustained claim validity tends to deter near-term entry
  • settlements often indicate practical barriers that prolong exclusivity

---

Does GENVOYA face biosimilar or biologic substitution pressure?

Short answer: No direct biosimilar analog exists for GENVOYA because it is a small-molecule fixed-dose oral therapy, not a biologic. Competitive pressure is driven by generic substitution of small-molecule combinations and by newer brand fixed-dose therapies, not biosimilars.

---

What formulation and method-of-use IP tends to be relevant for GENVOYA?

Short answer: For a fixed-dose combination, relevant IP commonly includes formulation (combination composition and stability) and method-of-use (treatment of HIV-1 infection under certain regimens or patient profiles).

Practical formulation IP implications

• Formulation patents can block “equivalent” substitutes if they claim:
  • specific compositions
  • specific physical forms, stability, or manufacturing attributes
• Method-of-use can affect the ability to market the same therapeutic regimen and label.

Financial linkage: Even if generic entry is possible for some protected aspects, method-of-use restrictions can delay payer switch and reduce competitive threat.

---

How does international market access and pricing affect GENVOYA revenue?

Short answer: Pricing controls and tender-based access in ex-US markets can drive different net revenue profiles and different timing of generic entry across jurisdictions.

Key cross-market dynamics

• EU and other regulated markets use different pricing/reimbursement controls and generic tender cycles.
• Patent coverage is jurisdiction-specific. A generic entry in one country can spill into pricing expectations and affect global brand valuation and negotiating leverage.

---

What are the commercial risks to GENVOYA from generic launch scenarios?

Short answer: The dominant generic-launch risk is a rapid conversion of covered lives to lower-cost equivalents after an authorized approval date and successful product listing on formularies, especially for stable patients who can switch without clinical disruption.

Generic launch scenario mechanics

• Brand-to-generic conversion speed: often driven by formulary tier change and pharmacy system updates.
• Payer backlash: payers shift volume quickly when net price falls.
• Physician behavior: HIV clinicians tend to maintain viral suppression when tolerable options exist; switching occurs when payer and availability pressure align.

Revenue effect pattern: A significant share drop is usually front-loaded after effective market entry, with slower residual attrition depending on remaining access barriers.

---

Key takeaways

• GENVOYA’s market dynamics are dominated by payer-driven formulary placement and competitive substitution by newer INSTI single-tablet regimens, especially Biktarvy, plus alternative fixed-dose options such as Symtuza.
• The financial trajectory has transitioned from uptake-led growth to maturity behavior where continuation among stable patients and net new starts determine net sales.
• The highest commercial risk is not clinical performance alone but IP and regulatory timing that governs generic substitution, through Orange Book patent coverage and any Paragraph IV litigation and settlements.
• “Patent strength” for GENVOYA should be evaluated as a layered Orange Book estate: core combination protection plus formulation and method-of-use claims that can block or slow generic conversion.
• Biosimilar pressure is not a direct factor because GENVOYA is a small-molecule fixed-dose regimen; the competitive threat is brand substitution and generic small-molecule entry timing.

---

FAQs

1) What product is GENVOYA competing against in US HIV formularies most directly?

Biktarvy and Symtuza are the principal US fixed-dose substitution pressures, with Triumeq influencing subsets based on abacavir eligibility and clinician preference.

2) How do payer rebate and contract dynamics change GENVOYA net sales even without patent expiration?

Net sales depend on gross-to-net dynamics. Even with stable prescriptions, contract renewal timing and formulary tiering can change net price and accelerate or slow switching.

3) What would a Paragraph IV decision mean for GENVOYA revenue timing?

A favorable outcome to challengers or a settlement that shortens delay can shift an at-risk or authorized generic entry earlier, creating step-change downside in net sales forecasts.

4) Does GENVOYA have biosimilar competition risk?

No. GENVOYA is a small-molecule oral therapy, so it faces generic competition and brand substitution, not biosimilar entry.

5) Are international generic entry events relevant to GENVOYA’s global strategy?

Yes. Patent and regulatory timelines differ by country, and earlier generic entry in any major market can affect global pricing leverage and anticipated competitive threats in other jurisdictions.

---

References

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. Gilead Sciences. GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) Prescribing Information. Gilead Sciences. https://www.gilead.com/
3. FDA. “ANDA and Patent Certification Guidance (including Paragraph IV framework).” U.S. Food and Drug Administration. https://www.fda.gov/

DrugChatter Q&A for GENVOYA

How does genvoya differ from stribild?
What are the signs of an allergic reaction to genvoya?
Is there a generic for Genvoya?